Case Studies

2025-08-25

SARS-CoV-2 Spike Peptides: 2021 Breakthrough in Neutralizing Antibody Research

This article highlights a 2021 Small Methods study that identified immunogenic peptides in the SARS-CoV-2 spike protein and isolated neutralizing monoclonal antibodies from COVID-19 patients. The research pinpointed key RBM epitopes (S431-454, S470-486, S501-515), with S470-486 emerging as an immunodominant target for diagnostics and therapeutics. Using phage display and ScFv libraries, the study validated epitope mapping and antibody functionality. Supported by AtaGenix’s expertise in phage display, protein expression, and assay development, this breakthrough offers a scalable approach for combating emerging viral pathogens, updated as of August 24, 2025.

2025-08-24

Discover Shrimp MANF’s Role in Anti-Inflammatory Research

This article explores a 2022 peer-reviewed study published in The Journal of Immunology, revealing that Mesencephalic Astrocyte-derived Neurotrophic Factor (MANF) in Litopenaeus vannamei (shrimp) acts as a conserved anti-inflammatory factor. The research demonstrates that extracellular MANF suppresses ERK phosphorylation and downregulates Dorsal (NF-κB) via a receptor-type tyrosine phosphatase (RPTP) in hemocytes, highlighting an ancient immune regulation mechanism with implications for neuroprotection, metabolism, and aging. Cross-species validation in human 293T cells further confirms MANF’s conserved role. Supported by AtaGenix, the study utilized advanced techniques including plasma proteomics, qPCR, and sandwich ELISA with phage display-generated monoclonal antibodies. This breakthrough, detailed as of August 24, 2025, underscores AtaGenix’s role in accelerating innate immunity research through custom antibody discovery, protein expression, and assay development.

2024-11-05

Antibody Fragment Production

Using AtaGenix's mammalian cell expression system, various antibody fragments have been successfully expressed, including scFv, VHH, Fab, and scFv-Fc-scFv, meeting diverse research and development needs.The accompanying images demonstrate the expression results and workflow of antibody production using this advanced system.

2024-11-05

Large-Scale Recombinant Antibody Production

Using AtaGenix's proprietary XtenCHO™ mammalian expression system, full-length IgG, VHH, scFv, and Fab antibody fragments were successfully expressed. The accompanying SDS-PAGE analysis demonstrates the system's ability to produce high-quality proteins:

2024-11-05

Chimeric Antibody Production

Chimeric antibody production combines the variable region of one species with the constant region of another to achieve optimal specificity and functionality. This approach ensures high binding affinity while maintaining robust stability and compatibility with downstream applications. Utilizing cutting-edge expression systems, production is scalable, cost-effective, and delivers high-purity antibodies suitable for therapeutic and research purposes.

2024-11-05

Hybridoma Sequencing

Hybridoma sequencing enables the precise identification of heavy and light chain variable regions of monoclonal antibodies. The data includes high-quality PCR amplification, colony validation gels, and sequencing results, ensuring accuracy in gene identification and antibody production.

2024-11-04

Xten™ Mab Single B Rabbit Monoclonal Antibody Development Case Study

Using rabbit single B-cell antibody technology, an Anti-human CD86 rabbit monoclonal antibody was developed. Rabbits with serum titers greater than 128K were selected, and PBMCs were isolated for flow sorting to obtain human CD86 antigen-specific B-cell plates.